Philadelphia gene therapy company battling cystic fibrosis gets a new owner
Philadelphia gene therapy company Spirovant Sciences changed owners twice in 2019— including being acquired by Sumitomo Dainippon Pharma of Japan last week as part of a $3 billion deal — and its CEO couldn’t be happier.
Sumitomo Dainippon Pharma and Roivant Sciences Sign Definitive Agreement for Strategic Alliance
Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) announced today that it has completed the procedure related to stock transfers, etc. and for the formation of a Strategic Alliance with Roivant Sciences (Head Offices: London and Basel; Founder & CEO: Vivek Ramaswamy) as of December 27, 2019. […]
How a small Philadelphia gene therapy company became part of a $3B deal
The article in the Philadelphia Business Journal features how Spirovant is developing two gene therapies to treat, and potentially cure, cystic fibrosis.
Sumitomo Dainippon Pharma and Roivant Sciences Sign Definitive Agreement for Strategic Alliance
Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506), a leading Japanese pharmaceutical company, and Roivant Sciences Ltd., a technology-enabled healthcare company, today announced that they have signed a definitive agreement for the creation of a novel and broad Strategic Alliance and